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In an ongoing research project, the Center for Persons with Disabilities at Utah 
State University, in collaboration with Dr. Susan E. Swedo at the National Institute of 
Mental Health, is evaluating genetic factors affecting the development of PANDAS 
(Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal 
infections). PANDAS is manifested in a group of prepubertal children who develop 
obsessive-compulsive disorder (OCD) following infection with Group A beta-hemolytic 
Streptococcal (GABHS) bacteria. We are assessing single nucleotide polymorphisms 
(SNPs) in the promoter region of tumor necrosis factor (TNF)-a and other cytokines 
known to be important in autoimmune diseases. 
Introduction 
GABHS bacterial infections, which cause strep throat and scarlet fever, have been 
implicated in the development of OCD in a certain group of prepubertal children. These 
children develop OCD symptoms after infection with GABHS bacteria. OCD symptoms 
are not present when there is no infection with GABHS but reappear upon subsequent 
infections. The presence or absence of GABHS bacteria during symptom manifestation 
or remission was confirmed by throat cultures or antibodies in the blood. 1 Children who 
are affected in this manner are classified as PANDAS patients. Five characteristics have 
been established to diagnose PANDAS: OCD/tic disorders, prepubertal onset, abrupt 
onset of symptoms and periods of increasing and decreasing symptom severity, 
neurological abnormalities, and symptom manifestation related to GABHS bacterial 
infections. 2 
It is believed that development of PANDAS may be due in part to genetic factors. 
We are assessing SNPs in the promoter regions of the cytokine genes of PANDAS 
patients. Cytokines are cellular proteins and glycoproteins produced by leukocytes. 
They serve multitudinous roles in the immune system. Cytokines are used as signals 
between leukocytes, cause cell proliferation, initiate apoptosis, serve as chemotaxis 
agents, and so on. Polymorphisms in the promoter region of a cytokine can cause an 
increase or decrease in production of the protein. Wilson et al. 3 showed that a SNP at the 
-308 position in the TNF-a promoter region was associated with an in increase in 
transcription of the gene. Other research supports this finding by demonstrating that this 
SNP is related to increased production of TNF-a. 4 Changes in the amount of cytokine can 
result in an altered immune response. For example, in chronic idiopathic 
thrombocytopenic purpura, an autoimmune disease affecting platelets, the amount of the 
cytokine tumor growth factor-Pl is significantly less in patients with the active disease 
than in patients in remission or controls. 5 TNF-a has also been implicated in a number of 
autoimmune diseases. Patients with systemic lupus erythematosus, for example, have 
increased levels of TNF-a gene expression in their bone marrow. 6 Modified cytokine 
levels may play a role in the development and susceptibility of PANDAS. 
Methods and Materials 
Determining DNA Extraction Procedure 
In order to perform the SNPs analyses, it is imperative that an appreciable amount 
of relatively pure DNA is collected. Initially, we attempted to collect DNA from white 
blood cells using the protocol described by Lash et al.7 In this procedure, the cells are 
lysed in the presence of silica, which is known to bind DNA. The silica is pelleted by 
centrifugation. The silica is mixed with a lysis buffer twice, a washing solution twice, 
and ethanol. After each solution is added, the silica is pelleted by centrifugation and the 
supernatant discarded. The pellet is then air-dried and incubated with an elution buffer. 
The solution is centrifuged and the supernatant containing the DNA collected. The first 
time we tried this protocol it resulted in unacceptable OD2601280 reading. We altered many 
parameters of the protocol such as centrifugation time, centrifugation speed, and amount 
of reagents used. Unfortunately, those attempts failed to produce desirable results as 
measured by the absorbance at 260 nm and OD2601280 reading. Agarose gel 
electrophoresis of the collected samples revealed that there was no DNA present. After 
further study, it was discovered that the protocol for collecting white blood cells from 
whole blood samples was ineffective. The white blood cell samples we were using had 
few cells and thus we were not obtaining enough DNA from them. We then tried to 
collect DNA from whole blood using the method described by Lash et al. This effort 
also resulted in unsatisfactory results. At this point we resorted to using commercial kits 
to extract the DNA. 
The first commercial kit we tried was QIAGEN® QIAamp DNA Blood Mini Kit 
(Cat. No. 51104). In this procedure, a protease and lysis buffer are added to the sample. 
It is incubated and ethanol is then added. The solution is placed on a spin column with a 
silica-gel membrane which binds the DNA. The column is centrifuged and the filtrate 
removed. The spin column with the bound DNA is rinsed with wash buffers, centrifuged, 
and the filtrates discarded. An elution buffer is added and the DNA collected from the 
column by centrifugation. This kit produced acceptable results the first time we used it, 
but the second time the results were inadequate. We then tried the QIAGEN® FelxiGene 
DNA Kit (Cat. No.51204). It produced satisfactory results. We are using this kit to 
extract genomic DNA from the samples for the study. 
DNA Extraction 
The National Institute of Mental Health provides whole blood samples from 
PANDAS patients, their parents, and controls. Using the QIAGEN® FelxiGene DNA 
Kit (Cat. No.51204) the genomic DNA is collected. The DNA is released from the cells 
by a lysis buffer and collected by centrifugation at 2000 g for 5 minutes. The genetic 
material is incubated with a protease and denaturation buffer at 65° C for 10 minutes. 
The DNA is precipitated with isopropanol and centrifuged for 3 minutes at 2000 g. The 
pellet is washed with 70% ethanol and centrifuged at 2000 g for 3 minutes. After air-
drying, the DNA pellet is resuspended in a hydration solution for 1 hour at 65° C. Once 
the DNA has been resuspended, the OD at 260 nm and 260/280 ratio is measured on the 
spectrophotometer. Samples are stored at -20° C until genotyping is done. 
Cytokine Genotyping 
Cytokine genotyping is performed using PEL-FREEZ® Clinical Systems, LLC 
Cytokine Genotyping Kit (Cat. No. 78920-10). This kit provides primers to amplify a 
number of specific cytokine polymorphisms. 5.6 -9.4 µ,g of DNA with OD26012Bo readings 
between 1.7-1.9 are required for the genotyping. The genomic DNA is combined with 
PCR buffer, Tag polymerase, and water. The samples are then distributed in the PCR 
wells, which contain specific primers for 48 reactions. The PCR reactions undergo 
thermal cycling with the following protocol: 2 minutes at 94° C; 10 cycles of 10 sat 94° 
C, 60 sat 65° C; 20 cycles of 10 sat 94° C, 50 sat 61 ° C, and 30 sat 72° C; and hold at 
4° C. The amplified regions are analyzed by performing electrophoresis on 2% agarose 
gel in TBE (0.5X) at 150 V. The gel is photographed and the cytokine genotypes of the 
individual are determined by completing the worksheet provided in the kit. 
Results and Discussion 
We have not received the complete sample set from the National Institute of 
Mental Health. The experiments, therefore, are not yet completed. We have extracted 
DNA from 30 samples. Thus far, the QIAGEN® FelxiGene DNA Kit has yielded 
between 15.0 and 47 .6 µ,g of DNA with OD26o1280 values between 1.539 and 1.782, 
discounting one sample with a particularly low result. Although some of the DNA may 
have lower OD26012so values than specified, the samples should be sufficient to perform 
the cytokine genotyping. The first cytokine genotyping that we performed resulted in 
indeterminable results. We hope to quickly resolve this problem and continue in our 
analyses. Once all the samples are received and the cytokine genotyping completed, our 
results will indicate whether PANDAS patients have inherited SNPs in their cytokine 
genes that render them susceptible to these disorders. With this and other information 
hopefully treatment will one day be devised to enable these children to overcome 
PANDAS. 
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